Enhanced Mineralization Potential of Vascular Cells from SM22α-Rankl (tg) Mice

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2012 Oct 12

PMID 23052229

Citations 7

Authors

S Morony

A P Sage

T Corbin

J Lu

Y Tintut

L L Demer

Affiliations

Soon will be listed here.

Abstract

Vascular calcification, prevalent in diabetes and chronic kidney disease, contributes to morbidity and mortality. To investigate the effect of receptor activator of NF-kB ligand (RANKL) on vascular calcification in vivo, transgenic mice, where RANKL expression was targeted to vascular smooth muscle cells using the SM22α promoter (SM22α-Rankl ( tg )), were created. Sixteen-month-old male SM22α-Rankl ( tg ) mice had higher body weight and higher serum calcium levels but lower lumbar bone mineral density (BMD) compared with age- and gender-matched wild-type (WT) littermates. BMD of long bones, body fat (percent of weight) of the leg, and serum levels of phosphate and RANKL were not significantly different. No significant differences in these parameters were observed in female mice. Histological analysis did not reveal calcium deposits in the aortic roots of SM22α-Rankl ( tg ) mice. To analyze the osteoblastic differentiation and mineralization potentials of vascular cells, aortic smooth muscle cells (SMCs) were isolated and cultured. Results showed that SM22α-Rankl ( tg ) SMCs had higher baseline alkaline phosphatase (ALP) activity but not baseline matrix calcification. When induced by the PKA agonist forskolin, ALP activity was greater in SM22α-Rankl ( tg ) than in WT SMCs. Real-time RT-qPCR revealed higher baseline expression of ALP and ankylosis genes but lower osteoprotegerin gene in SM22α-Rankl ( tg ) SMCs. Matrix mineralization induced by inorganic phosphate or forskolin was greater in SM22α-Rankl ( tg ) than in WT SMCs. Treatment of these cells with the ALP inhibitor levamisole abolished forskolin-induced matrix mineralization but not inorganic phosphate-induced matrix mineralization. These findings suggest that RANKL overexpression in the vasculature may promote mineralization potential.

Citing Articles

Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fed knockout mice.

Chang G, Cheng W, Fan H, Chen H, Lan Y, Chen M Front Cell Dev Biol. 2023; 11:1158812.

PMID: 37091976 PMC: 10117689. DOI: 10.3389/fcell.2023.1158812.

Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.

Fehervari L, Frigy A, Kocsis L, Szabo I, Szabo T, Urkon M Diagnostics (Basel). 2021; 11(5).

PMID: 33923139 PMC: 8145213. DOI: 10.3390/diagnostics11050764.

Differing calcification processes in cultured vascular smooth muscle cells and osteoblasts.

Patel J, Bourne L, Davies B, Arnett T, Macrae V, Wheeler-Jones C Exp Cell Res. 2019; 380(1):100-113.

PMID: 31004580 PMC: 6520648. DOI: 10.1016/j.yexcr.2019.04.020.

A GTPase-activating protein-binding protein (G3BP1)/antiviral protein relay conveys arteriosclerotic Wnt signals in aortic smooth muscle cells.

Ramachandran B, Stabley J, Cheng S, Behrmann A, Gay A, Li L J Biol Chem. 2018; 293(21):7942-7968.

PMID: 29626090 PMC: 5971440. DOI: 10.1074/jbc.RA118.002046.

Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice.

Shamsuzzaman S, Onal M, St John H, Pike J J Cell Biochem. 2017; 118(12):4240-4253.

PMID: 28419519 PMC: 5645213. DOI: 10.1002/jcb.26074.

References

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A . Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109(18):2175-80. DOI: 10.1161/01.CIR.0000127957.43874.BB. View

Tintut Y, Parhami F, Bostrom K, Jackson S, Demer L . cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification. J Biol Chem. 1998; 273(13):7547-53. DOI: 10.1074/jbc.273.13.7547. View

Chen N, ONeill K, Duan D, Moe S . Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002; 62(5):1724-31. DOI: 10.1046/j.1523-1755.2002.00625.x. View

Lepore J, Cheng L, Lu M, Mericko P, Morrisey E, Parmacek M . High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis. 2005; 41(4):179-84. DOI: 10.1002/gene.20112. View

Jung K, Lein M, Hosslin K, Grosse A, Roth S, Possinger K . Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers. 2002; 17(3):177-81. DOI: 10.1177/172460080201700306. View

Li L, Miano J, Mercer B, Olson E . Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol. 1996; 132(5):849-59. PMC: 2120743. DOI: 10.1083/jcb.132.5.849. View

Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K . Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106(10):1192-4. DOI: 10.1161/01.cir.0000031524.49139.29. View

Min H, Morony S, Sarosi I, Dunstan C, Capparelli C, Scully S . Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000; 192(4):463-74. PMC: 2193236. DOI: 10.1084/jem.192.4.463. View

10.

Johnson K, Polewski M, Van Etten D, Terkeltaub R . Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol. 2004; 25(4):686-91. DOI: 10.1161/01.ATV.0000154774.71187.f0. View

11.

Hofbauer L, Khosla S, Dunstan C, Lacey D, Boyle W, Riggs B . The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000; 15(1):2-12. DOI: 10.1359/jbmr.2000.15.1.2. View

12.

Hofbauer L, Schoppet M, Schuller P, Viereck V, Christ M . Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf). 2004; 60(2):214-9. DOI: 10.1046/j.1365-2265.2003.01969.x. View

13.

Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S . RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res. 2009; 104(9):1041-8. DOI: 10.1161/CIRCRESAHA.108.189001. View

14.

Schoppet M, Sattler A, Schaefer J, Herzum M, Maisch B, Hofbauer L . Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003; 88(3):1024-8. DOI: 10.1210/jc.2002-020775. View

15.

Olesen M, Skov V, Mechta M, Mumm B, Rasmussen L . No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol. 2012; 362(1-2):149-56. DOI: 10.1016/j.mce.2012.06.004. View

16.

Huang M, Sage A, Lu J, Demer L, Tintut Y . Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem Biophys Res Commun. 2008; 374(3):553-8. PMC: 2570192. DOI: 10.1016/j.bbrc.2008.07.062. View

17.

Ewence A, Bootman M, Roderick H, Skepper J, McCarthy G, Epple M . Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008; 103(5):e28-34. DOI: 10.1161/CIRCRESAHA.108.181305. View

18.

Li X, Yang H, Giachelli C . BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis. 2008; 199(2):271-7. PMC: 3249145. DOI: 10.1016/j.atherosclerosis.2007.11.031. View

19.

Kyung Nam H, Liu J, Li Y, Kragor A, Hatch N . Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J Biol Chem. 2011; 286(45):39059-71. PMC: 3234731. DOI: 10.1074/jbc.M111.221689. View

20.

Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N . Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab. 2002; 20(6):337-44. DOI: 10.1007/s007740200049. View